Pharmacokinetic properties of single-Dose primaquine in papua new guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria

Brioni Moore, S. Salman, J. Benjamin, M. Page-Sharp, L.J. Robinson, E. Waita, K.T. Batty, P.M. Siba, I. Müeller, Timothy Davis, I. Betuela

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance, and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0.5 and 1.0 mg/kg of body weight) was conducted in 28 healthy glucose-6-phosphate dehydrogenase-normal Papua New Guinean children, aged 5 to 12 years, to facilitate development of abbreviated high-dose regimens. Dosing was with food and was directly observed, and venous blood samples were drawn during a 168-h postdose period. Detailed safety monitoring was performed for hepatorenal function and hemoglobin and methemoglobin concentrations. Plasma concentrations of PMQ and its metabolite carboxyprimaquine (CPMQ) were determined by liquid chromatography-mass spectrometry and analyzed using population pharmacokinetic methods. The derived models were used in simulations. Both single-dose regimens were well tolerated with no changes in safety parameters. The mean PMQ central volume of distribution and clearance relative to bioavailability (200 liters/70 kg and 24.6 liters/ h/70 kg) were within published ranges for adults. The median predicted maximal concentrations (Cmax) for both PMQ and CPMQ after the last dose of a 1.0 mg/kg 7-day PMQ regimen were approximately double those at the end of 14 days of 0.5 mg/kg daily, while a regimen of 1.0 mg/kg twice daily resulted in a 2.38 and 3.33 times higher Cmax for PMQ and CPMQ, respectively. All predicted median Cmax concentrations were within ranges for adult high-dose studies that also showed acceptable safety and tolerability. The present pharmacokinetic data, the first for PMQ in children, show that further studies of abbreviated high-dose regimens are feasible in this age group. © 2014, American Society for Microbiology. All Rights Reserved.
    Original languageEnglish
    Pages (from-to)432-439
    JournalAntimicrobial Agents and Chemotherapy
    Volume58
    Issue number1
    DOIs
    Publication statusPublished - Jan 2014

    Fingerprint Dive into the research topics of 'Pharmacokinetic properties of single-Dose primaquine in papua new guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria'. Together they form a unique fingerprint.

  • Projects

    Cite this